All In Biotech

Drug Trial Radar · NCT07104344

Study of CM355 in Patients With Systemic Lupus Erythematosus

A Single-center, Open-label, Single-arm Clinical Study to Observe the Safety and Efficacy of CM355 in the Treatment of Refractory Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

5

Actual

Start

Sep 25, 2025

Primary completion

Jun 15, 2026

Study completion Sep 1, 2027

Sponsor

Lead sponsor
Second Xiangya Hospital of Central South UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to investigate the safety and efficacy of CM355 in patients with refractory SLE.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • CM355Biological

    CM355 injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. adverse events (AE)Time frame: Throughout the study,an average of about 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.